Format

Send to

Choose Destination
Anticancer Res. 2016 Feb;36(2):611-5.

Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck.

Author information

1
Department of Otolaryngology, Head and Neck Surgery, University Hospital Ulm, Germany. thierauf.julia@gmail.com
2
Department of Otolaryngology, Head and Neck Surgery, University Hospital Ulm, Ulm, Germany.
3
Section of Experimental and Translational Head and Neck Oncology, Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.
4
Department of Pathology, University Hospital Ulm, Ulm, Germany.
5
Department of Pathology, University of Pittsburgh, Pittsburgh, PA, U.S.A.
6
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Köln, Köln, Germany.
7
Section of Experimental and Translational Head and Neck Oncology, Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany Research Group Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center, Heidelberg, Germany.

Erratum in

Abstract

BACKGROUND:

Adenoid cystic carcinoma of the head and neck (ACC) is a rare tumor entity which originates from the salivary glands. The prognosis remains poor, as the tumor tends to exhibit perineural invasion and frequently develops distant metastases. The submaxillary gland androgen-regulated protein 3A (SMR3A) belongs to a gene family producing opiorphin homologs and is physiologically secreted by salivary glands. Expression of SMR3A has been identified as an unfavorable risk factor in survival of patients with squamous cell carcinoma in the head and neck, but its value as a prognostic biomarker for ACC has not been addressed.

MATERIALS AND METHODS:

Tissue sections from primary ACC (n=86) and healthy glandular tissue as reference, were stained by immunohistochemistry. SMR3A expression levels were correlated with clinical and pathological features, including overall survival.

RESULTS:

All patients had undergone surgery and 67 received adjuvant radiotherapy. The median disease-free survival (DFS) was 37 months and the median overall survival (OS) was 75 months. Prominent SMR3A expression in tumor cells was found in 24 of 86 patients (27,9%), and was inversely correlated with a male gender (p=0.009). There was no significant correlation between SMR3A expression and DFS, metastasis-free survival or OS.

CONCLUSION:

Our data demonstrate for the first time decreased levels of SMR3A in ACC compared to normal glandular tissue. These data suggest a context-dependent regulation of SMR3A expression in the pathogenesis of distinct subtypes of head and neck tumors, and support the assumption that detection of SMR3A expression serves as a surrogate for aberrant differentiation into mucosal- or glandular-like cells in ACC and head and neck squamous cell carcinoma.

KEYWORDS:

Adenoid cystic carcinoma; SMR3A; head and neck cancer; immunohistochemistry

PMID:
26851015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center